Gastroenterology Research and Practice / 2015 / Article / Tab 1 / Review Article
Transplantation of Autologous Mesenchymal Stem Cells for End-Stage Liver Cirrhosis: A Meta-Analysis Based on Seven Controlled Trials Table 1 The key characteristics of trials included.
Study Country
Cause of
Number of patients
Purity
Type of MSC
Number of cells *
Therapy
Route
Control Maximum follow-up I C
Salama et al., 2010 [13 ] Egypt Mixed 90 50 IMP CD34+ and CD133+ aBM-MSCs 0.5 × 108 Once Portal TST 6 months Amer et al., 2011 [12 ] Egypt Hepatitis C 20 20 IP aBM-MSCs stimulated with HGF 2 × 108 Once Intrasplenic or intrahepatic TST 6 months Peng et al., 2011 [16 ] China Hepatitis B 39 77 FC aBM-MSCs N.A. Once Hepatic artery TST 12 months El-Ansary et al., 2012 [14 ] Egypt Hepatitis C 15 10 FC aBM-MSCs 106 /Kg Once Intravenous TST 6 months Mohamadnejad et al., 2013 [15 ] Iran Mixed 15 12 FC aBM-MSCs 1.2–2.95 × 108 Once Intravenous Placebo 12 months Xu et al., 2014 [18 ] China Hepatitis B 27 29 FC aBM-MSCs 8.45 ± 3.28 × 108 Once Hepatic artery TST 6 months Salama et al., 2014 [17 ] Egypt Hepatitis C 20 20 FC aBM-MSCs 0.5 × 108 Once Intravenous TST 6 months
I = intervention; C = control; MSC = mesenchymal stem cell; aBM-MSCs = autologous BM-MSCs; TST: traditional supportive treatment; IP = immunophenotyping; FC = flow cytometry; IMP = immunomagnetic purification;
